Stock LUCD LUCID DIAGNOSTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Lucid Diagnostics Inc.

Equities

LUCD

US54948X1090

Market Closed - Nasdaq
Other stock markets
 01:30:00 29/06/2024 am IST 		5-day change 1st Jan Change
0.82 USD -5.64% Intraday chart for Lucid Diagnostics Inc. +18.34% -41.84%
13/05 Transcript : Lucid Diagnostics Inc., Q1 2024 Earnings Call, May 13, 2024
13/05 Lucid Diagnostics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Lucid Diagnostics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Lucid Diagnostics Inc. Announces Legacy Esophageal Cell Collection Device Subject of Class II FDA Recall
CI
Lucid Diagnostics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Lucid Diagnostics Inc. Announces Positive Data from the First Prospective Clinical Validation Study of Esoguard Esophageal Precancer Testing in A Screening Population
CI
Lucid Diagnostics Inc. Executes Contract to Provide Esoguard® Esophageal Precancer Testing as A Covered Benefit for 9/11 Responders and Survivors
CI
Lucid Diagnostics Inc. and Pavmed Inc. Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
CI
Lucid Diagnostics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Lucid Diagnostics Inc. Releases Positive Data from First Prospective Clinical Utility Study of Esoguard®? Esophageal Precancer Detection
CI
Lucid Diagnostics Inc. Releases Positive Data Demonstrating Clinical Utility of EsoGuard®? Esophageal Precancer Detection in Fire Fighters
CI
Lucid Diagnostics to Provide Esophageal Pre-Cancer Screening to Ancira Auto Employees
MT
Lucid Diagnostics Inc. Executes First Direct Employer Contract to Provide EsoGuard®? Esophageal Precancer Testing as an Employee Benefit
CI
Lucid Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Lucid Diagnostics Launches First Esoguard® Mobile Test Unit
CI
Lucid Diagnostics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Lucid Diagnostics Inc. Announces Findings from Two Clinical Studies of its EsoGuard®? Esophageal DNA Test and EsoCheck®? Cell Collection Device
CI
Lucid Diagnostics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Lucid Diagnostics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Elon Musk's challenge: Stay ahead of the competition
RE
Lucid Diagnostics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Lucid Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LUCD Stock
  4. News Lucid Diagnostics Inc.
  5. Highlights